Glaukos Shares Rise After FDA Approves NDA Supplement for iDose TR

By Chris Wack

Glaukos shares were 6% higher, at $125.46, Wednesday after the Food and Drug Administration approved a new drug application labeling supplement allowing for re-administration of iDose TR using a repeat treatment protocol.

The company said the FDA approval is in response to Glaukos' 2025 NDA labeling supplement application, and reflects accumulated clinical evidence supporting the safety and tolerability of repeat use for iDose TR.

Under the updated labeling, the company said, physicians may now re-administer iDose TR more than once to patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

In clinical studies, Glaukos said iDose TR has demonstrated a favorable long-term corneal safety profile, with no clinically significant corneal endothelial cell loss observed through three years across both the Phase 3 and Phase 2b studies.

iDose TR is designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 28, 2026 13:25 ET (18:25 GMT)